Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
Sponsor: Stealth BioTherapeutics Inc.
Listed as NCT02976038, this PHASE2 trial focuses on Primary Mitochondrial Disease and remains terminated or withdrawn. Sponsored by Stealth BioTherapeutics Inc., it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE2
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 6 earlier versions
-
May 2019 — May 2020 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Jun 2018 — May 2019 [monthly]
Enrolling By Invitation PHASE2
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
-
Mar 2017 — May 2018 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stealth BioTherapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Akron, United States
- • Boston, United States
- • Pittsburgh, United States
- • San Diego, United States